0.64% -0.0056

Biofrontera Inc (BFRI)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Biofrontera Inc Stock (BFRI) Company Profile

Biofrontera Inc

Healthcare (1118)

781-245-1325

120 PRESIDENTIAL WAY,, WOBURN

Nächster Verdiensttermin

Neueste SEC-Einreichungen

BFRI's Discussions on Twitter

Compare BFRI vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BFRI Biofrontera Inc	0.8644	10.13M	37.17M	-17.57M	-12.01M	-1.8172
TAK Takeda Pharmaceutical Co Adr	17.84	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	114.68	48.74B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.04	44.85B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.73	34.12B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	540.66	23.35B	3.13B	1.27B	1.12B	26.39

Biofrontera Inc Aktie (BFRI) Neueste Nachrichten

Finanzdaten der Biofrontera Inc-Aktie (BFRI)

Biofrontera Inc (BFRI)

Biofrontera Inc Stock (BFRI) Company Profile

Compare BFRI vs TAK, ZTS, HLN, TEVA, UTHR

Biofrontera Inc Aktie (BFRI) Neueste Nachrichten

Biofrontera (BFRI) to Release Earnings on Thursday - Defense World

Are healthcare shares trailing behind Align Technology (ALGN) in performance this year? - Bitget

PTA-Adhoc: Biofrontera AG: Financial Guidance for FY 2026 - TradingView

Market Rankings: Is Biofrontera Inc backed by strong institutional buying2026 Opening Moves & Verified Swing Trading Watchlists - baoquankhu1.vn

Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Bitget

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - The Manila Times

Biofrontera Inc. to Report Fourth Quarter and Full Year - GlobeNewswire

Biofrontera reports Phase 2b acne trial results for Ameluz PDT - Investing.com India

Biofrontera Reports Positive Phase 2b Acne Trial Results - TipRanks

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - The Manila Times

Biofrontera reports positive Phase 2b Ameluz PDT results for moderate to severe acne - TradingView

Biofrontera Inc. Reports Positive Phase 2b Results - GlobeNewswire

Is Biofrontera Inc. backed by strong institutional buyingQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn

Loss Report: Does Biofrontera Inc have a sustainable dividendDollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn

BFRIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Will Biofrontera Inc. stock go up in YEAR2025 Top Gainers & Risk Controlled Stock Alerts - mfd.ru

Bank Watch: Is Biofrontera Inc a play on infrastructure spendingJuly 2025 Final Week & AI Enhanced Execution Alerts - baoquankhu1.vn

Biofrontera wins patent ruling against Sun Pharma in dispute By Investing.com - Investing.com Canada

Biofrontera wins patent ruling against Sun Pharma in dispute - Investing.com

Biofrontera reports USPTO decision on Sun Pharma’s challenged claims - TipRanks

Biofrontera Wins Key PTAB Ruling in Sun Patent Dispute - TipRanks

Biofrontera (NASDAQ: BFRI) wins PTAB decision on Sun Pharma patent claims - Stock Titan

U.S. Patent Office Issues Final Written Decision Finding - GlobeNewswire

Gains Recap: Will Biofrontera Inc stock go up in YEAR2025 Trading Recap & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn

Is Biofrontera Inc. stock technically oversoldWeekly Stock Analysis & Community Consensus Trade Signals - mfd.ru

Growth Value: Can Biofrontera Inc Equity Warrant sustain its profitabilityLong Setup & Weekly Breakout Watchlists - baoquankhu1.vn

Trading Action: Does Biofrontera Inc have high return on assets2025 Risk Factors & AI Forecasted Entry/Exit Points - baoquankhu1.vn

Can Biofrontera Inc Equity Warrant sustain its profitabilityMarket Growth Report & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn

How Biofrontera Inc. Equity Warrant stock responds to policy changesJuly 2025 Retail & Low Drawdown Momentum Ideas - mfd.ru

Fundamentals Check: Can Biofrontera Inc Equity Warrant navigate macro headwindsQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn

Biofrontera completes key study for Ameluz skin treatment expansion By Investing.com - Investing.com South Africa

Biofrontera Emerges as Stronger Biotech Stock Compared to RenovaCare - National Today

Biofrontera completes key study for Ameluz skin treatment expansion - Investing.com

Biofrontera Inc (NASDAQ: BFRI) recently announced that the database lock for its Phase I pharmacokinetic study of Ameluz® for actinic keratosis on the trunk and extremities has been completed. - Bitget

Biofrontera Inc. Announces Database Lock of Phase 1 - GlobeNewswire

Travel Stocks: Does Biofrontera Inc have a sustainable dividend2025 Biggest Moves & High Return Trade Opportunity Guides - baoquankhu1.vn

Biofrontera reports positive phase 3 data for Ameluz in actinic keratosis - MSN

Bull Run: Is now the right time to enter Biofrontera Inc Equity Warrant - baoquankhu1.vn

BFRI SEC FilingsBiofrontera Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Fundamentals Check: Why ETFs are accumulating Biofrontera AG (B8FK) stockJuly 2025 PostEarnings & Stepwise Trade Execution Plans - mfd.ru

Signal Recap: Is Biofrontera Inc stock a hidden gemTrade Volume Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn

Is Biofrontera Inc. stock near bottom after declineMarket Trend Review & AI Forecast Swing Trade Picks - mfd.ru

Biofrontera Inc. (NASDAQ:BFRI) Sees Significant Decline in Short Interest - Defense World

Will Biofrontera Inc. Equity Warrant benefit from AI trendsDollar Strength & Scalable Portfolio Growth Methods - mfd.ru

Biofrontera announces FDA filing acceptance of supplemental new drug application for Ameluz® PDT in superficial Basal Cell Carcinoma - marketscreener.com

Biofrontera Announces FDA Filing Acceptance of Supplemental - GlobeNewswire

Biofrontera's light-based option for common skin cancer under FDA review - Stock Titan

Biofrontera’s Ameluz shows strong results in actinic keratosis trial By Investing.com - Investing.com Australia

Biofrontera announces positive results in phase 3 study of Ameluz® PDT - marketscreener.com

Biofrontera Reports Positive Phase 3 Ameluz PDT Results - TipRanks

Biofrontera’s Ameluz shows strong results in actinic keratosis trial - Investing.com

Finanzdaten der Biofrontera Inc-Aktie (BFRI)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie BFRI